Holen Sie sich die Stockscreener-App
4.26
3.15%
0.13
Handel nachbörslich:
4.31
0.05
+1.17%
Schlusskurs vom Vortag:
$4.13
Offen:
$4.17
24-Stunden-Volumen:
170.36K
Relative Volume:
1.23
Marktkapitalisierung:
$57.66M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-73.52M
KGV:
-6.4545
EPS:
-0.66
Netto-Cashflow:
$-100.45M
1W Leistung:
+0.47%
1M Leistung:
-15.48%
6M Leistung:
-9.17%
1J Leistung:
-54.73%
1-Tages-Spanne:
$4.13
$4.30
1-Wochen-Bereich:
$4.02
$4.38
52-Wochen-Spanne:
$3.61
$11.09
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Vergleichen Sie DTIL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.26 | 57.66M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
precision biosciences reports voting outcomes at annual shareholder meeting By Investing.com - Investing.com Australia
precision biosciences reports voting outcomes at annual shareholder meeting - Investing.com
Precision BioSciences Holds Annual Stockholder Meeting - TipRanks
Precision BioSciences (DTIL): Rating Reaffirmed at Buy with $60 Target | DTIL Stock News - GuruFocus
(DTIL) Proactive Strategies - news.stocktradersdaily.com
Precision BioSciences: Q1 Earnings Snapshot - CT Insider
Precision BioSciences Reports Q1 2025 Financial Results - TipRanks
Transcript : Precision BioSciences, Inc.Special Call - marketscreener.com
Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus
Precision BioSciences Reports Q1 Results and Business Update - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Precision BioSciences Reports First Quarter 2025 Financial Resul - GuruFocus
DTIL Reports Strong Start to 2025 with Clinical Progress | DTIL Stock News - GuruFocus
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | DTIL Stock News - GuruFocus
Precision Biosciences Q1 Income From Operations USD -22.112 Million - marketscreener.com
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace
Precision BioSciences Accelerates PBGENE-DMD Program for DMD - TipRanks
Precision BioSciences Accelerates Development of PBGENE-DMD With - GuruFocus
Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 - BioSpace
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 | DTIL Stock News - GuruFocus
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) - GuruFocus
iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings - Business Wire
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting | DTIL Stock News - GuruFocus
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) April 29, 2025 - BioSpace
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Precision BioSciences Strengthens Gene Editing Team with Strategic RSU Awards to New Hires - Stock Titan
Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - TradingView
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment By Investing.com - Investing.com South Africa
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - BioSpace
Precision BioSciences stock rises following FDA Fast Track designation By Investing.com - Investing.com India
Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene E - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia
Precision BioSciences stock rises following FDA Fast Track designation - Investing.com Australia
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus
Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv - marketscreener.com
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precision Biosciences Inc-Aktie (DTIL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Buehler Kevin | Director |
Jun 25 '25 |
Buy |
4.16 |
5,076 |
21,116 |
28,137 |
| Buehler Kevin | Director |
Mar 26 '25 |
Buy |
4.67 |
4,523 |
21,122 |
13,235 |
| Brown Melinda | Director |
Mar 26 '25 |
Buy |
4.75 |
1,839 |
8,735 |
9,057 |
| Germano Geno J | Director |
Mar 25 '25 |
Buy |
5.30 |
3,250 |
17,225 |
11,057 |
| Amoroso Michael | President and CEO |
Mar 24 '25 |
Sale |
5.56 |
964 |
5,360 |
109,540 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):